As demonstrated, due to its flexibility, this approach already resulted in improved inhibitory properties of enzyme inhibitors designed to target cancer-associated CA-IX or compounds that proved to have better antiparasitic activity than the boron-substituted analogues. The gene discussed is CA9; the disease is cancer.